Result of AGM

December 7, 2020
RNS Number : 8167H
Renalytix AI PLC
07 December 2020


Renalytix AI plc

("RenalytixAI" or the "Company")


Result of AGM


Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that at the Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed.


The results of the AGM are detailed below:


Votes in Favour

(% of votes cast)

Votes against

(% of votes cast)


Votes withheld

Resolution 1


42,245,505 (91.38%)


3,986,275 (8.62%)


Resolution 2


41,548,352 (89.87%)


4,685,392 (10.13%)


Resolution 3

46,228,154 (99.99%)


1,526 (0.01%)


Resolution 4


46,190,220 (99.91%)

43,624 (0.09%)



Resolution 5


46,071,032 (99.66%)

157,813 (0.34%)



Resolution 6


46,095,710 (99.73%)


127,083 (0.27%)


Resolution 7


45,551,130 (99.88%)


54,530 (0.12%)





Renalytix AI plc

James McCullough, CEO

Via Walbrook PR

Stifel (Nominated Adviser, Joint Broker)

Tel: 020 7710 7600

Alex Price / Nicholas Moore 

Investec Bank plc (Joint Broker)

Tel: 020 7597 4000

Gary Clarence / Daniel Adams

Walbrook PR Limited

Tel: 020 7933 8780 or

Paul McManus / Lianne Cawthorne

Mob: 07980 541 893 / 07584 391 303



About Kidney Disease 

Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. The Centers for Disease Control and Prevention (CDC) estimates that 15% of US adults, or 37 million people, currently have chronic kidney disease (CKD).  Further, the CDC reports that 9 out of 10 adults with CKD do not know they have it and 1 out of 2 people with very low kidney function who are not on dialysis do not know they have CKD*. Kidney disease is referred to as a "silent killer" because it often has no symptoms and can go undetected until a very advanced stage.  Each year kidney disease kills more people than breast and prostate cancer. Every day, 13 patients in the United States die while waiting for a kidney transplant.



About RenalytixAI

RenalytixAI is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. RenalytixAI's products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.